Cargando…

Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia

BACKGROUND: Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Habbash, Fatema, Al-Bati, Wegdan, Al-Hashim, Howra, Aldossari, Maryam, Alali, Ahmed, Alalyani, Khalid, Al-Ebrahim, Zainab, Hamed, Nouf, Eraqe, Samma, Binayfan, Ziyad, Al Marri, Azzam, Aljaber, Thamer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741829/
https://www.ncbi.nlm.nih.gov/pubmed/36514312
http://dx.doi.org/10.2147/JBM.S386594
_version_ 1784848400036921344
author Habbash, Fatema
Al-Bati, Wegdan
Al-Hashim, Howra
Aldossari, Maryam
Alali, Ahmed
Alalyani, Khalid
Al-Ebrahim, Zainab
Hamed, Nouf
Eraqe, Samma
Binayfan, Ziyad
Al Marri, Azzam
Aljaber, Thamer
author_facet Habbash, Fatema
Al-Bati, Wegdan
Al-Hashim, Howra
Aldossari, Maryam
Alali, Ahmed
Alalyani, Khalid
Al-Ebrahim, Zainab
Hamed, Nouf
Eraqe, Samma
Binayfan, Ziyad
Al Marri, Azzam
Aljaber, Thamer
author_sort Habbash, Fatema
collection PubMed
description BACKGROUND: Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. AIM: To evaluate endocrine complications in beta thalassemia major patients (2–30 years) in the Eastern Province of Saudi Arabia and compare the onset of endocrine complications among compliant and noncompliant patients. Moreover, we assessed the barriers that hinder compliance with chelating therapy. METHODS: A cross-sectional study was conducted on 89 patients (43 males and 46 females) aged 2 to 30 years attending different hospitals in the Eastern Province of Saudi Arabia. A semi-structured questionnaire was used to collect demographic data and medical histories. The questionnaires were completed by face-to-face interviews with the patients or their caregivers, and the required laboratory data were retrieved from the medical records of patients. RESULTS: The most prevalent abnormality was underweight detected in (40.9%) of patients, followed by subclinical hypothyroidism (37.7%), short stature (35.2%), hypothyroidism in (17.0%) and diabetes mellitus in (13.6%). A significant difference between those who were compliant with iron chelation therapy and those who were not in terms of the prevalence of short stature (P value=0.05) and hypothyroidism (P value=0.05). The percentage of patients who were not compliant with chelation therapy was 21.6% and 9.1% of patients were not taking them at all. CONCLUSION: Despite the role of chelation therapy in the management of iron overload, the risk of secondary endocrine and metabolic complications remained considerable. Subclinical hypothyroidism and short stature were the most frequent endocrine complications encountered in this study.
format Online
Article
Text
id pubmed-9741829
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97418292022-12-12 Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia Habbash, Fatema Al-Bati, Wegdan Al-Hashim, Howra Aldossari, Maryam Alali, Ahmed Alalyani, Khalid Al-Ebrahim, Zainab Hamed, Nouf Eraqe, Samma Binayfan, Ziyad Al Marri, Azzam Aljaber, Thamer J Blood Med Original Research BACKGROUND: Endocrinopathies and metabolic complications are common in beta thalassemia major patients receiving blood transfusions. Chelation therapy has a role in preventing or delaying such complications. However, patients may face difficulties adhering to chelation therapy for several reasons. AIM: To evaluate endocrine complications in beta thalassemia major patients (2–30 years) in the Eastern Province of Saudi Arabia and compare the onset of endocrine complications among compliant and noncompliant patients. Moreover, we assessed the barriers that hinder compliance with chelating therapy. METHODS: A cross-sectional study was conducted on 89 patients (43 males and 46 females) aged 2 to 30 years attending different hospitals in the Eastern Province of Saudi Arabia. A semi-structured questionnaire was used to collect demographic data and medical histories. The questionnaires were completed by face-to-face interviews with the patients or their caregivers, and the required laboratory data were retrieved from the medical records of patients. RESULTS: The most prevalent abnormality was underweight detected in (40.9%) of patients, followed by subclinical hypothyroidism (37.7%), short stature (35.2%), hypothyroidism in (17.0%) and diabetes mellitus in (13.6%). A significant difference between those who were compliant with iron chelation therapy and those who were not in terms of the prevalence of short stature (P value=0.05) and hypothyroidism (P value=0.05). The percentage of patients who were not compliant with chelation therapy was 21.6% and 9.1% of patients were not taking them at all. CONCLUSION: Despite the role of chelation therapy in the management of iron overload, the risk of secondary endocrine and metabolic complications remained considerable. Subclinical hypothyroidism and short stature were the most frequent endocrine complications encountered in this study. Dove 2022-12-07 /pmc/articles/PMC9741829/ /pubmed/36514312 http://dx.doi.org/10.2147/JBM.S386594 Text en © 2022 Habbash et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Habbash, Fatema
Al-Bati, Wegdan
Al-Hashim, Howra
Aldossari, Maryam
Alali, Ahmed
Alalyani, Khalid
Al-Ebrahim, Zainab
Hamed, Nouf
Eraqe, Samma
Binayfan, Ziyad
Al Marri, Azzam
Aljaber, Thamer
Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
title Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
title_full Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
title_fullStr Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
title_full_unstemmed Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
title_short Endocrine Complications and the Effect of Compliance with Chelation Therapy in Patients with Beta Thalassemia Major in Eastern Province of Saudi Arabia
title_sort endocrine complications and the effect of compliance with chelation therapy in patients with beta thalassemia major in eastern province of saudi arabia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741829/
https://www.ncbi.nlm.nih.gov/pubmed/36514312
http://dx.doi.org/10.2147/JBM.S386594
work_keys_str_mv AT habbashfatema endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT albatiwegdan endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT alhashimhowra endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT aldossarimaryam endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT alaliahmed endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT alalyanikhalid endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT alebrahimzainab endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT hamednouf endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT eraqesamma endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT binayfanziyad endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT almarriazzam endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia
AT aljaberthamer endocrinecomplicationsandtheeffectofcompliancewithchelationtherapyinpatientswithbetathalassemiamajorineasternprovinceofsaudiarabia